<DOC>
	<DOCNO>NCT02603328</DOCNO>
	<brief_summary>The study aim demonstrate extend course atorvastatin therapy reduce lesional iron deposition without increase risk rebleeding ( acute hemorrhage ) patient cerebral cavernous malformation ( CCM ) . Subjects randomize daily atorvastatin ( 20,40 80mg PO ) placebo follow 36 month , clinically overt CCM hemorrhage attrition drug relate adverse event . Subjects undergo total four MRI scan biomarker study , serial clinical assessment .</brief_summary>
	<brief_title>Atorvastatin Therapy Cerebral Cavernous Malformation : A Proof Concept Phase I/II Trial</brief_title>
	<detailed_description>The propose study prospective phase I/II randomize , placebo-controlled , single-blinded , single-site clinical trial . Sixty CCM subject randomize 2:1 fashion receive either atorvastatin ( 40 mg PO ) placebo , All subject undergo baseline three interval MRI study 6 , 18 36 month throughout three-year study period . Systematic dose escalation regime follow base lesional brain vascular permeability assess dynamic contrast enhance quantitative perfusion ( DCEQP ) . At six month MRI scan , subject &gt; 30 % reduction either lesional brain permeability continue dose . If neither lesional background brain permeability exhibit &gt; 30 % reduction , dose escalate 80 mg absence side effect . Enrolled subject investigator assess dose relate DCEQP iron deposition lesion Quantitative Susceptibility Mapping ( QSM ) blind treatment group allocation .</detailed_description>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Hemangioma , Cavernous , Central Nervous System</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>1 . Diagnosis CCM genotype support relevant imaging study . 2 . Symptomatic CCM bleeding event within 2 year prior enrollment . 3 . Must willing/able travel study site study visit ( baseline , 6 month , 18 month 36 month ) course study period . 1 . Premenopausal woman breastfeed , pregnant likely get pregnant study period . 2 . Previous cranial irradiation . 3 . Failure pas MRI safety screening ( claustrophobia , metal implant . . . etc ) 4 . Known allergy intolerance gadolinium . 5 . Severely impaired renal function ( eGFR &lt; 60ml/min ) , active renal disease status postkidney transplant . 6 . Statin therapy , indication , within 12 month precede enrollment . 7 . Indication use statin medication current approve indication , unrelated CCM 8 . Known allergy intolerance statins 9 . Liver dysfunction active liver disease ( include chronic viral hepatitis ) define baseline serum transaminase level twice upper range normal . 10 . Previous diagnosis skeletal muscle disorder cause ( myopathy ) , baseline creatine kinase level five time upper range normal . 11 . Currently treat likely need treatment one prohibit medication list section 5.3 . 12 . Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement . 13 . Serious illness ( require systemic treatment and/or hospitalization ) subject either complete therapy clinically stable therapy , opinion site investigator , least 30 day prior study entry . 14 . Any condition investigator believe would pose significant hazard subject investigational therapy initiate , include condition result precipitate myopathy ( e.g . HIV , uncontrolled hypothyroidism ) . 15 . In investigator 's opinion , patient unstable , would benefit specific intervention rather treatment atorvastatin . 16 . Inability unwillingness subject legal guardian/representative give write informed consent . 17 . No documentation valid healthcare insurance . 18 . No medical record confirmation primary care physician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Cerebral cavernous malformation</keyword>
	<keyword>Statins</keyword>
	<keyword>MRI</keyword>
	<keyword>Permeability</keyword>
	<keyword>Quantitative susceptibility mapping</keyword>
</DOC>